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ABSTRACT (70 words) 
 
Based on social indicators collected within the TEMPRANO-ANRS12239 trial, we assessed the social 
consequences of early ART initiation in West Africa. We did not observe any significant differences in 
the levels or the time trends of various social indicators, including union status, HIV disclosure and HIV-
related discrimination, between early and deferred ART initiation. Early ART does not carry detectable 
adverse social consequences that could impair its clinical and preventive benefits. 
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MAIN TEXT (999 words)  
Two randomized trials recently documented important clinical benefits of very early antiretroviral 
therapy (ART) [1,2]. These results complemented previous evidence of the preventive effect of early 
ART [3], so that treatment and prevention can now be seen as converging goals. Beyond preventive 
and clinical effects of early ART initiation, its possible consequences on social dimensions of patients’ 
lives remain to be documented. 
Pathways linking ART initiation to repercussion on various social dimensions are complex and partially 
understood. ART initiation is associated with HIV status disclosure to relatives [4–6], which can in turn 
lead to increased social support but also to rejection [7,8]. Similarly, the impact of ART on stigma and 
discrimination seems ambiguous [9–11]. Positive impact on professional activity has been more 
consistently documented [12,13]. However, these associations have been observed among people 
initiating ART at low CD4 count or with HIV-related symptoms. Negative events associated with ART 
may be more likely among people with high CD4 count, among whom treatment initiation may reveal a 
hitherto unapparent HIV infection. 
With new international guidelines recommending ART for every HIV-infected person, trends should 
progressively move toward earlier treatment initiation [14]. The social repercussions of ART initiation 
among people perceiving themselves, or being perceived by their relatives, as healthy  have not been 
documented yet, although they may have a substantial impact on acceptation and adherence, and 
ultimately on the public health impact of this strategy. 
Relying on social data collected within the TEMPRANO-ANRS12136 randomized controlled trial, we 
aimed to assess the impact of early ART on various dimensions reflecting social inclusion and the 
experience of discrimination. 
 
The present socio-behavioral study was nested in the TEMPRANO-ANRS12136 trial, a randomized 
trial of early ART that was conducted in Abidjan (Côte d’Ivoire) [1,15]. At inclusion, ART-naïve 
participants presenting no criteria for starting ART were randomized to initiate ART immediately (“early 




[16,17]. Standardized socio-behavioral questionnaires were completed during face-to-face interviews 
conducted at inclusion, and then during clinical visits occurring around 12 and 24 months after inclusion.  
Questionnaires included items related to household composition, couple status, HIV status disclosure 
inside and outside the household, professional activity and experience of discriminations. From these 
items, we constructed the following indicators: living alone (yes/no), being in union (yes/no), having 
disclosed HIV status inside (yes/no) or outside (yes/no) the household, having had a regular 
professional activity in the last 6 months (yes/no) and having experienced HIV-related discriminations 
in the last 12 months (yes/no). 
All trial participants having completed a questionnaire at one or more of the following timings were 
included in the analysis: i) M0 (inclusion visit), ii) M12 (12±3 months after inclusion), and iii) M24 (24±6 
months after inclusion). For each indicator, levels and time trends from M0 to M24 were assessed and 
compared between deferred and early ART groups. Generalized Estimating Equations (GEE) with a 
logit link were used to account for multiple observations. Models included ART group and time period 
(coded as a three-level factor: M0/M12/M24) as covariates. Interaction terms between ART group and 
time period were added in order to test differential time trends between ART groups.  
 
 
A total of 2061 participants (deferred ART: 1028; early ART: 1033) completed at least one socio-
behavioral questionnaire (Table S1). Median baseline CD4 count was 469/mm3 (IQR 379-577), 91% 
were WHO stage 1 or 2. After randomization, participants’ socio-demographic and clinical 
characteristics distributions were balanced between both groups (Table S2). 
Levels and time trends in social indicators according to ART strategy are presented in Figure 1. Twenty-
four months after inclusion, we did not observe any significant differences in the level reported by 
participants between the early and deferred ART group for any of the indicators (Table S3). The 
interaction term between randomization group and time was not significant for any of the indicators 
(each p>0.25), suggesting that the observed time trends between M0 and M24 were not significantly 






Motivation to start and adhere to ART may be difficult for people at early stage of HIV infection [18,19]. 
By increasing the visibility of HIV infection among apparently healthy people, one could have feared 
that early ART would lead to HIV disclosure, and potentially to discrimination, union breaking and 
loneliness. Moreover, adverse consequences on occupational activity could have been expected due 
to potential side effects of ART [20]. Documenting the absence of detectable associated negative social 
events is thus reassuring with regard to the social feasibility of very early ART and may help remove 
barriers to entry in treatment. 
This study reports an absence of evidence supporting adverse social effect of early ART. Several 
elements suggest that, had substantial effects existed, this study would have successfully detected 
them. First, we relied on a large sample size that would have allowed detecting even small effect sizes. 
Second, information was collected face-to-face by trained interviewers using standardized 
questionnaires. Randomization ensured an equivalent distribution of confounders between the control 
and intervention groups. As follow-up was similar in both groups, differential report bias appears 
unlikely. However, the studied indicators did not cover key socio-behavioural issues such as intimate 
partner violence or mental health. Monitoring the implementation of the updated recommendations for 
ART initiation may help assess these issues.  
To our knowledge, no previous study has addressed the issue of the repercussion of early ART on 
diverse social dimensions. These results have been obtained within a trial that documented strong 
clinical individual benefits of early ART alongside evidence for reduced sexual risk behaviours following 
early entry into care and decreased risk of transmission due to the effect of ART on viral load [1,15,22]. 
As a whole, these results show that early ART in a West African context appears to combine clinical 
and preventive benefits that are not impaired by potential adverse social effects. This reinforces the 
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Figure 1 : Social indicators reported at inclusion (M0). 12-month (M12) and 24-month visits among 
participants on deferred vs. early antiretroviral therapy (ART). 






Table S1 : Participants’ baseline sociodemographic and clinical data according to randomisation 
group. 
  Deferred ART (N=1028) Early ART (N=1033) p 
Sex   0.163 
Men 235 (22.9%) 210 (20.3%)  
Women 793 (77.1%) 823 (79.7%)  
Age   35 [30 – 42]  35 [30 – 42] 0.563 
Educational level  0.385 
None 245 (23.8%) 276 (26.7%)  
Primary 301 (29.3%) 293 (28.4%)  
Secondary 342 (33.3%) 341 (33.0%)  
>Secondary 140 (13.6%) 123 (11.9%)  
Religion  0.620 
None 39 (3.8%) 35 (3.4%)  
Muslim 258 (25.1%) 263 (25.5%)  
Christian 720 (70.0%) 729 (70.6%)  
Other 11 (1.1%) 6 (0.6%)  
Nationality  0.693 
Ivorian 916 (89.1%) 926 (89.6%)  
Other 112 (10.9%) 107 (10.4%)  
WHO clinical stage   0.866 
1 673 (65.5%) 665 (64.4%)  
2 264 (25.7%) 272 (26.3%)  
3 91 (8.8%) 96 (9.3%)  
CD4 count cell (/mm3)  459 [360 - 568]  466 [373 - 578] 0.202 
Counts (%) and Chi2 p-values are presented for categorical measures. Percent are computed as a fraction of 








Table S2 :  Levels of social indicators 24 months after inclusion according to ART strategy. 
 
 At M24 
  OR Early/Deferred ART [CI 95%] 
Living alone 1.16 [0.80 ; 1.70] 
In union 1.10 [0.92 ; 1.32] 
HIV  disclosure inside the household 1.07 [0.86 ; 1.32] 
HIV  disclosure outside the household 1.09 [0.88 ; 1.35] 
Lack of regular   professional activity 0.98 [0.78 ; 1.24] 
Experience of HIV-related discrimination in the last 
12 months 1.11 [0.57 ; 2.18] 
 
Odds Ratio have been estimated using Generalized Estimating Equations (GEE) accounting for ART group, time 







Table S3 :  Time trends in social indicators. 
 
 Model with interaction term1  Model without interaction term1 
 Deferred ART  Early ART  Interaction 
p 
 Overall 
  ORM24/M0 [CI 95%]  ORM24/M0 [CI 95%]   ORM24/M0 [CI 95%] 
Living alone 1.34 [0.84 ; 2.14]  1.72 [1.08 ; 2.74]  0.582  1.52 [1.09 ; 2.12] 
In union 0.81 [0.70 ; 0.94]  0.89 [0.77 ; 1.03]  0.534  0.85 [0.77 ; 0.94] 
HIV  disclosure 
inside the household 1.28 [1.04 ; 1.57]  1.08 [0.88 ; 1.32]  0.404  1.18 [1.02 ; 1.36] 
HIV  disclosure 
outside the 
household 
1.15 [0.94 ; 1.40]  1.44 [1.19 ; 1.75]  0.245  1.29 [1.13 ; 1.48] 
Lack of regular 
professional activity 0.82 [0.62 ; 1.07]  0.84 [0.65 ; 1.10]  0.928  0.83 [0.69 ; 1.01] 
Experience of HIV-
related discrimination 
in the last 12 months 
0.71 [0.35 ; 1.42]   0.61 [0.33 ; 1.13]   0.253   0.65 [0.41 ; 1.04] 
 
1 Interaction terms between ART group and time period.  






Table S4: Social indicators according to ART strategy and time since inclusion (among women, men, and both sex). 
      Deferred ART   Early ART   Interaction p1 
  Timing   % ORM24/M0 95%CI p   % ORM24/M0 95%CI p     
Women             
Living alone            0,605 
 M0  3.1 - - -  3 - - -   
 M24  4.1 1,28 [0,68 ; 2,40] 0,447  5.1 1,85 [1,00 ; 3,44] 0,051   
In union            0,379 
 M0  47.1 - - -  47.4 - - -   
 M24  39.2 0,76 [0,65 ; 0,90] 0,001  41.6 0,88 [0,75 ; 1,03] 0,101   
HIV  disclosure inside the household         0,550 
 M0  60.5 - - -  68.2 - - -   
 M24  63.5 1,17 [0,93 ; 1,46] 0,176  65.5 1,02 [0,82 ; 1,28] 0,833   
HIV  disclosure outside the household         0,169 
 M0  68 - - -  59.8 - - -   
 M24  69.3 1,16 [0,92 ; 1,47] 0,195  72.5 1,58 [1,27 ; 1,96] 0,000   
Lack of regular  professional activity         0,856 
 M0  39.0 - - -  35.3 - - -   
 M24  33.3 0,76 [0,55 ; 1,03] 0,077  31.3 0,82 [0,60 ; 1,10] 0,188   
Experience of HIV-related discrimination in the last 12 months       0,392 
 M0  2.8 - - -  4.1 - - -   
  M24   2.2 0,81 [0,38 ; 1,72] 0,592   2.3 0,60 [0,32 ; 1,15] 0,122     
1 Interaction terms between ART group and time period. 
Odds Ratio have been estimated using Generalized Estimating Equations (GEE) accounting for ART group, time period, and an interaction term. 






Table S4 (continued): Social indicators according to ART strategy and time since inclusion (among women, men, and both sex). 
      Deferred ART   Early ART   Interaction p1 
  Timing   % ORM24/M0 95%CI p   % ORM24/M0 95%CI p     
Men             
Living alone            0,751 
 M0  9.1 - - -  9.5 - - -   
 M24  12.8 1,51 [0,75 ; 3,07] 0,25  14.1 1,35 [0,65 ; 2,79] 0,424   
In union             0,837 
 M0  60.6 - - -  71.6 - - -   
 M24  61.7 1,03 [0,74 ; 1,44] 0,852  65.8 0,88 [0,60 ; 1,30] 0,529   
HIV  disclosure inside the household         0,705 
 M0  60.0 - - -  66.1 - - -   
 M24  75.0 1,94 [1,19 ; 3,16] 0,008  74.8 1,04 [0,66 ; 1,62] 0,870   
HIV  disclosure outside the household         0,576 
 M0  53.2 - - -  56.4 - - -   
 M24  59.8 1,07 [0,72 ; 1,59] 0,732  59.1 1,42 [0,82 ; 2,44] 0,207   
Lack of regular   professional activity         0,989 
 M0  25.0 - - -  30.9 - - -   
 M24  26.7 1,02 [0,58 ; 1,81] 0,931  31.5 0,96 [0,54 ; 1,72] 0,905   
Experience of HIV-related discrimination in the last 12 months2        
 M0  2.0 - - -  1.4 - - -   
  M24   0.5 - - -   1.1 - - -     
1 Interaction terms between ART group and time period. 
2 GEE were impossible to fit due to insufficient numbers.  
Odds Ratio have been estimated using Generalized Estimating Equations (GEE) accounting for ART group, time period, and an interaction term. 






Table S4 (continued): Social indicators according to ART strategy and time since inclusion (among women, men, and both sex). 
      Deferred ART   Early ART   Interaction p1 
  Timing   % ORM24/M0 95%CI p   % ORM24/M0 95%CI p     
Both sex             
Living alone            0,605 
 M0  4.6 - - -  4.2 - - -   
 M24  6.1 1,85 [1,00 ; 3,44] 0,051  7.1 1,28 [0,68 ; 2,40] 0,447   
In union             0,379 
 M0  49.2 - - -  49.2 - - -   
 M24  44.1 0,88 [0,75 ; 1,03] 0,101  46.4 0,76 [0,65 ; 0,90] 0,001   
HIV  disclosure inside the household         0,55 
 M0  58.9 - - -  64.5 - - -   
 M24  64.7 1,02 [0,82 ; 1,28] 0,833  66.2 1,17 [0,93 ; 1,46] 0,176   
HIV  disclosure outside the household         0,169 
 M0  64.6 - - -  61.2 - - -   
 M24  67.7 1,58 [1,27 ; 1,96] 0,000  69.5 1,16 [0,92 ; 1,47] 0,195   
Lack of regular   professional activity         0,856 
 M0  36.3 - - -  35.2 - - -   
 M24  31.9 0,82 [0,60 ; 1,10] 0,188  31.5 0,76 [0,55 ; 1,03] 0,077   
Experience of HIV-related discrimination in the last 12 months1       0,392 
 M0  2.6 - - -  3.4 - - -   
  M24   1.9 0,60 [0,32 ; 1,15] 0,122   2.1 0,81 [0,38 ; 1,72] 0,592     
1 Interaction terms between ART group and time period. 
Odds Ratio have been estimated using Generalized Estimating Equations (GEE) accounting for ART group, time period, and an interaction term. 
OR: Odds Ratio; CI: Confidence Interval; M0: At inclusion; M24: 24 months after inclusion.  
 
